DESCRIPTION
A 26-year-old man reported with the chief complaints of dry mouth, facial swelling and difficulty opening his mouth. His medical records indicated that he had been treated for nasopharyngeal squamous cell carcinoma when he was 10 years old. He had undergone two cycles of chemotherapy (cisplatin, 5-fluorouracil and vincristine) followed by 60 Gray of cobalt-60 beam therapy to the nasopharynx and bilateral cervical lymph nodes. After defaulting on follow-up for nearly 14 years, he presented with the following dental and maxillofacial features that are classically the late side-effects of antineoplastic therapy: [1] [2] [3] ▸ Xerostomia due to atrophy and fibrosis of the salivary glands. ▸ Trismus (figure 1) due to myofibrosis, loss of soft tissue flexibility, and hypomobility of the temporomandibular joint. ▸ Altered dental development including arrested development of teeth/roots, short, blunted or tapered roots, enlarged pulp chambers (taurodontism), microdontia and hypoplasia (figure 2). The patient's past dental history indicated that a few mobile teeth, probably with compromised periodontal support, had exfoliated spontaneously, resulting in partially edentulous arches. ▸ Features of osteoradionecrosis including suppuration, cortical destruction, sequestration and pathological fracture (figure 2). Clinically, these features presented as pain, an orofacial fistula in the left cheek with suppurative discharge, a 3×3 cm soft swelling in the left pre-auricular region filled with pus (figure 3), and exposed necrotic bone in the left posterior alveolar region of the mandible with ulceration/necrosis of the overlying mucosa.
▸ Skeletal growth disturbance manifested as mandibular hypoplasia, causing skeletal class II malocclusion ( figure 3 ). ▸ Multiple caries lesions (because of predisposition due to xerostomia, altered salivary characteristics and microbial flora, and constraints on oral hygiene measures due to pain, stomatodynia, etc).
Learning points
▸ The adverse effects of oncotherapy on the developing orofacial tissues may present long after the completion of active therapy. ▸ Information about these late effects should be given to the patient at the time of informed consent. ▸ Long term follow-up and proper oral hygiene measures (including the use of topical fluorides) in such cases is extremely important. 
